February 13, 2026 7:35am

The inflation indicator and earnings, Friday could be a risk-on kind of day

Earnings:  Moderna (MRNA +$0.09 or +0.22% to $44.20 pre-open)

Pre-open Signals: 5 Positive Indications with a lot of drops; if you understand probabilities, the inevitable is easier to maneuver

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

 

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

RMi Closing Bell: Sector’s share pricing demolition … https://www.regmedinvestors.com/articles/14309

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Friday: The pre-open Dow futures are DOWN -0.23% or (-113 points), the S&P futures are DOWN -0.23% or (-16 points) and the Nasdaq futures are DOWN -0.24% or (-60 points)

  • U.S. stock futures are deep in the pool, Friday, 2/13
  • European markets traded lower,
  • Asia Pacific markets are also lower

 

Economic Data: January’s consumer price index report.

  • The inflation gauge is expected to show a 2.5% advance from a year earlier. On a month-over-month basis, economists call for a 0.3% increase.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -669.42 points or -1.34%, the S&P closed DOWN -108.71 points or -1.57% while the Nasdaq closed DOWN -469.319 points or -2.04%
  • Wednesday: The Dow closed DOWN -66.74 points or -0.13%, the S&P closed DOWN -0.34 points or -0.00% while the Nasdaq closed DOWN -36.007 points or -0.16%
  • Tuesday: The Dow closed UP +52.27 points or +0.10%, the S&P closed DOWN -23.02 points or -0.33% while the Nasdaq closed DOWN -136.196 points or -0.59%
  • Monday: The Dow closed UP +20.20 points or +0.04%, the S&P closed UP +32.51 points or +0.47% while the Nasdaq closed UP +207.457 points or +0.90%
  • Last week: The S&P 500 closed down -0.1%, the Nasdaq fell -1.84% and the Dow rose +2.5%
  • The previous week: The S&P 500 closed up +0.04% and the Nasdaq -0.2%, while the Dow dropped -0.2%.
  • January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

 

Q1/26 – Q1 February – 3 positive and 6 negative closes

  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes  

Q4

  • December, 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • More coming ... 1 today,  earnings next week as sector releases Qs and FY25 …

IQIA Holdings (IQV) closed down -$8.26 after Wednesday’s -$5.29 after Tuesday’s -$10.22 after Monday’s +$5.27 with a positive +$1.05 or +0.62% pre-open

Vertex (VRTX) closed up +$3.78 after Wednesday’s -$2.24, Tuesday’s -$7.39 and Monday’s -$7.05 with a positive +$2.98 or +0.64% pre-open

uniQure NV (QURE) closed down -$1.74 after Wednesday’s -$0.60 after Tuesday’s -$1.34 after Monday’s +$0.40 with a positive +$0.53 or +2.37% pre-open

Supernus Therapeutics (SUPN) closed down -$1.49 after Wednesday’s +$0.13 with a positive +$0.48 or +0.96% pre-open

 

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

Stock futures slipped on Friday morning after a downbeat day for the U.S. stock market. Traders also looked ahead to a key consumer inflation report due Friday morning.

The 3 major averages are on pace for weekly losses, with the S&P 500 and Dow off more than 1% through Thursday’s close. The Nasdaq is on track for a 1.9% decline in the period. <CNBC>

Still trending … “Expectation ... choppy trading, undrinkable econ “mash”, more earnings and still waiting for more econs as I prepare for more snow!”

 

Since, the Q4 and FY25 earnings reporting cycle ….

  • Tuesday - 2/24 – AxoGen (AXGN) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – Ionis Pharmaceuticals (IONS)

 

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

February – 2nd week

  • 2/12 – Thursday closed negative with 7 incliners, 33 decliners and 2 flats
  • 2/11 - Wednesday closed negative with 12 incliners, 25 decliners and 3 flats
  • 2/10 - Tuesday closed negative with 19 incliners, 20 decliners and 1 flat
  • 2/9 - Monday closed positive with 23 incliners, 14 decliners and 3 flats

February continues …

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat
  • 2/3 - Tuesday closed negative with 18 incliners, 21 decliners and 1 flat    
  • 2/2 - Monday closed positive with 29 incliners, 10 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.